Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Abbott to pay $175 million for Ibis

This article was originally published in Scrip

Executive Summary

Abbott is to pay $175 million for Ibis Biosciences after it exercised its option to buy the remaining equity ownership in the Isis Pharmaceuticals subsidiary. The move will strengthen Abbott's capabilities in identifying infectious agents in hospital and clinical settings. Earlier this year, Abbott invested $40 million in Ibis in exchange for 18.6% of Ibis's equity. Isis will receive earn-out payments tied to post-closing sales of Ibis systems, including instruments and assay kits. The transaction is expected to close in January 2009. Ibis's technology also has biodefence applications and use in microbial forensics (Scrip Online, July 3rd, 2008).



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts